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Mutations and inactivation of phosphatase and ten-
sin homolog deleted from chromosome 10 (PTEN)
are observed in 15%–25% of cases of human T cell
acute lymphoblastic leukemia (T-ALL). Pten deletion
induces myeloproliferative disorders (MPDs), acute
myeloid leukemia (AML), and/or T-ALL inmice. Previ-
ous studies attributed Pten-loss-related hematopoi-
etic defects and leukemogenesis to excessive acti-
vation of phosphatidylinositol 3-kinase (PI3K)/AKT/
mTOR signaling. Although inhibition of this signal
dramatically suppresses the growth of PTEN-null
T-ALL cells in vitro, treatment with inhibitors of this
pathwaydoesnot causeacomplete remission in vivo.
Here, we report that focal adhesion kinase (Fak), a
protein substrate of Pten, also contributes to T-ALL
development in Pten-null mice. Inactivation of the
FAK signaling pathway by either genetic or pharma-
cologic methods significantly sensitizes both murine
and human PTEN-null T-ALL cells to PI3K/AKT/
mTOR inhibitionwhencultured in vitro on feeder layer
cells or a matrix and in vivo.
INTRODUCTION
PTEN mutations are detected in 15%–25% of T cell acute
lymphoblastic leukemia (T-ALL) patients (Gutierrez et al., 2009;
Jotta et al., 2010; Zuurbier et al., 2012). Inactivation of PTEN
and constitutive activation of its downstream signaling pathways
are associated with early treatment failure, drug resistance, and
poor prognosis (Jotta et al., 2010; Piovan et al., 2013). Thus, it
should be useful to completely elucidate the roles of the PTEN
downstream signaling pathways in the pathogenesis of T-ALLCellfor the development of less toxic targeted therapies for this fatal
disease.
PTEN possesses both lipid and protein phosphatase activities
(Lee et al., 1999; Tamura et al., 1998). It represses growth factor/
cytokine-stimulated cell growth and survival by repressing phos-
phatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling through
dephosphorylation of phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) (Stambolic et al., 1998). It also dephosphorylates focal
adhesion kinase (FAK), thus inhibiting integrin-induced adhesion
and migration by suppressing the turnover of focal adhesions
and cytoskeletal reorganization (Gu et al., 1998; Guo and Gian-
cotti, 2004; Tamura et al., 1998). It was reported that T-ALL
development in Pten-null mice could be repressed by inactiva-
tion of the PI3K/Akt/mTor signaling (Kalaitzidis et al., 2012; Sub-
ramaniam et al., 2012). Preclinical studies showed that PI3K/
AKT/mTOR inhibitors induce apoptosis and repress the growth
of T-ALL cell lines and primary human T-ALL cells, suggesting
that this signaling pathway might be a promising target for
T-ALL therapy (Evangelisti et al., 2011; Subramaniam et al.,
2012). However, PI3K/AKT/mTOR inhibition did not cause com-
plete remission in vivo (Rodon et al., 2013), suggesting that there
might be an additional survival signal that compensates for inhi-
bition of PI3K/AKT signaling in PTEN-null T-ALL. As an important
target of PTEN, the role of FAK has not been studied in the etiol-
ogy and progression of T-ALL induced by PTEN mutations.
FAK is a non-receptor tyrosine kinase. In response to integrin
and/or chemokine stimulation, activated FAK promotes cell
adhesion, spreading, motility, proliferation, and anchorage-
dependent survival by inducing the activation of its downstream
signals, including p130Cas/Rac/CDC42, Rho/Gap/RhoA, extra-
cellular signal-regulated kinase/mitogen-activated protein ki-
nase, Wnt/b-catenin and NF-kB (Desgrosellier and Cheresh,
2010; Guan, 2010; Mitra and Schlaepfer, 2006; Schaller, 2010).
Dysregulation of FAK has been detected in multiple cancers,
including breast, brain, prostate, and liver cancer (Guan, 2010;
Mitra and Schlaepfer, 2006; Pylayeva et al., 2009). In theseReports 10, 2055–2068, March 31, 2015 ª2015 The Authors 2055
cancers, the activity of FAK generally correlates with increased
tumor malignancy, drug resistance, and metastasis (Golubov-
skaya, 2014; Lechertier and Hodivala-Dilke, 2012). FAK also
plays an essential role in regulating the self-renewal of cancer
stem cells (Guan, 2010). Thus, FAK has been suggested to be
a potentially advantageous target for cancer therapy (Golubov-
skaya, 2014).
Despite the liquid nature of blood and the peripheral circula-
tion of leukemic cells (LCs), the majority of leukemia-initiating
cells (LICs) reside in the bone marrow (BM), spleen (SP), and
other organs where they adhere to their niches; this could pro-
vide in vivo signals to activate FAK in LCs (Konopleva and Jor-
dan, 2011). Clinically, increased FAK activity is correlated with
high blast cell counts and shorter survival times (Despeaux
et al., 2011; Recher et al., 2004). We speculated that signals
emanating from niches might stimulate FAK activation in LCs,
which is normally restricted by PTEN. In PTEN-mutant T-ALL
cells, activated FAK may play a critical role in disease initiation
and progression and the development of drug resistance by
providing a survival signal in LCs parallel to PI3K/AKT/mTOR
signaling. To test this hypothesis, we inactivated FAK by genetic
and pharmacologic methods to study the functions of FAK in
PTEN-null T-ALL cells.
RESULTS
The Activity of Fak Is Significantly Increased in Pten/
Thymocytes
Loss of Pten causes myeloproliferative disorders (MPDs), acute
myeloid leukemia (AML), and/or T-ALL in Mx-1-Cre+Ptenfx/fx
mice (Pten/), in which Pten is deleted in nearly 100% of adult
hematopoietic cells (HCs) after three to five polyinosine-polycy-
tidine (pI:pC) injections (Yilmaz et al., 2006; Zhang et al., 2006).
Repression of PI3K/Akt/mTor signaling by inhibitors or genetic
deletion largely suppresses the defects of HSCs and leukemia
development, but none of these inhibitors or deletions can
completely block leukemia development in Pten/mice (Kalait-
zidis et al., 2012; Yilmaz et al., 2006). Thus, it is possible that
another potential downstream target(s) of Pten that can be acti-
vated in vivo compensates for PI3K/Akt/mTor inhibition in the
development of leukemia in Pten/ mice. Pten dephosphory-
lates both the lipid substrate PIP3, which is activated by PI3K,
and protein targets such as Fak (Tamura et al., 1998), which is
activated by adhesion signals (Mitra and Schlaepfer, 2006). We
predicted that FAKmight mediate such compensatory signaling.
To test this hypothesis, we determined the expression of Fak in
wild-type (WT) hematopoietic stem/progenitor cells from BM
and differentiated HCs from SP and thymus (TH) (Figure 1A).
Fak was expressed at low levels in LinSca1+c-Kit+ cells (LSK)
and at very low levels in progenitor cells (common myeloid pro-
genitor, granulocyte-macrophage progenitor, megakaryocyte
erythroid progenitor, and common lymphoid progenitor cells),
myeloid cells (Gr1+Mac1+), macrophages (F4/80+), B cells
(B220+), and erythroid lineage cells (Ter119+). Fakwas highly ex-
pressed in platelet precursors (CD41+), as well as CD4CD8,
CD4+CD8+, CD4+CD8, and CD4CD8+ T lymphocytes.
Although the expression of Fak was comparable between WT
and Pten/, Pten deletion enhanced the activation of both Akt2056 Cell Reports 10, 2055–2068, March 31, 2015 ª2015 The Authorand Fak in thymocytes, as shown by the increased levels
of pAkt/pS6k and pFak/pSrc, respectively. Neither Cre expres-
sion by itself nor pI:pC treatment activated either signal (Fig-
ure 1B). In the four subtypes of thymocytes (Figures 1C and
1D; Figure S1), the expression of Fak was not changed by Pten
deletion. However, Pten deletion enhanced Fak activation in
all thymocytes, especially in CD4+CD8 cells, which consist
of T-ALL cells in Pten/ mice (Zhang et al., 2011). These
data suggest that hyper-activated Fak in CD4+CD8 cells may
contribute to T-ALL development in Pten/ mice.
Fak Deletion Significantly Delays T-ALL Development
but Does Not Affect MPD in Pten/ Mice
Mx-1-Cre+Ptenfx/fx mice were crossed with Fakfx/fx mice to
generateMx-1-Cre+Ptenfx/fxFakfx/fx mice to study the role of Fak
in hematopoietic defects in Pten/ mice. Initially, the mice
received five pI:pC injections as reported previously (Yilmaz
et al., 2006; Zhang et al., 2006). The hematopoietic alterations
amongMx-1-Cre+Ptenfx/fx,Mx-1-Cre+Fakfx/fx,Mx-1-Cre+Ptenfx/fx
Fakfx/+, and Mx-1-Cre+Ptenfx/fxFakfx/fx mice were analyzed 20–
25 days after pI:pC treatments. Mx-1-Cre+, Mx-1-Cre+Ptenfx/+
Fakfx/+, Mx-1-Cre+Ptenfx/+, Mx-1-Cre+Fakfx/+, or Ptenfx/fxFakfx/fx
mice from the same or a comparable litter were used asWT con-
trols (no phenotypic differences among these mice; data not
shown). Consistent with previous reports, Mx-1-Cre+Fakfx/fx
mice (Fak/ hereafter) had no significant hematopoietic defects
(Figures 2E–2H and 3A–3C; Figures S2A and S2B), except for a
small but significant increase in platelet numbers (Figure S2C)
(Vemula et al., 2010). 20 to 25 days after 5 3 pI:pC injections,
both Mx-1-Cre+Ptenfx/fx and Mx-1-Cre+Ptenfx/fxFakfx/+ mice
(Pten/ hereafter [no differences between them]) and Mx-1-
Cre+Ptenfx/fxFakfx/fx mice (Pten/Fak/ hereafter) developed
MPDs, as shown by a significant increase in Gr-1+Mac-1+ cells
in BM, peripheral blood (PB), and SP. The percentage of B220+
and Gr1+Mac1+ cells (Figures S2A and S2B) or nucleated cells
in PB (Figures S2F and S2G) was not affected by Fak deletion.
Interestingly, compared to Pten/ mice, there was a mild but
statistically significant impact onwhite blood cell (WBC), platelet,
and red blood cell (RBC) counts (Figure S2C) and a subtle
increased survival, though without statistical significance, in
Pten/Fak/ mice (Figure S2D). These data suggest that Fak
is less essential for MPD development in Pten/mice.
Without pI:pC treatment, Mx-1-Cre+Ptenfx/fx mice develop T-
ALL 3–4 months after birth, but they rarely develop MPDs (Zhang
et al., 2011). VEC-Cre+Ptenfx/fx mice, in which Pten is deleted in
40% of HCs, also develop only T-ALL (Guo et al., 2008). Thus,
to study the role of Fak in T-ALL induced by Pten deletion, we
used a reduced regimen of pI:pC to induce deletion in a fraction
of HCs. We injected WT, Pten/, Pten/Fak/, and Fak/
miceoncewith 25mg/kgpI:pC. Tendaysafter injection, c-Kit+ he-
matopoietic stem and progenitor cells (HSPCs) and thymocytes
were isolated. We used colony PCR to determine the efficiency
ofPtenandFakdeletion in thesecells. This pI:pC regimen induced
Pten deletion in 55% of c-Kit+ HSPCs and 25% of thymocytes,
both inPten/ andPten/Fak/mice.Fakwasco-deletedwith
Pten in Pten/Fak/ thymocytes (Figure 2A). This result was
confirmedbymeasuringprotein levelsofPtenandFak (Figure2B).
Thus, a reduced regimen of pI:pC induced both Pten and Faks
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Figure 1. Akt and Fak Signals Are Highly Activated in Pten/ Thymocytes
(A) Fak expression in LinSca1+c-Kit+ (LSK), LSKFlk2, LSKFlk2+, common myeloid progenitor (CMP), granulocyte-macrophage progenitor (GMP), megakar-
yocyte erythroid progenitor (MEP), common lymphoid progenitor (CLP), Gr1+Mac1+, Ter119+, and CD41+ cells isolated from BM; F4/80+, B220+ cells from SP;
and CD4CD8, CD4+CD8+, CD4+CD8, and CD4CD8+ cells from TH of WT mice.
(B) Fak and Akt activities in WT and Pten/ thymocytes. Controls: thymocytes from mice without pI:pC injection; WT tail tip fibroblasts (TTF). Images are
representative of three independent experiments. Quantification (Multi Gauge 3.0) relative to WT control after normalized to loading controls.
(C and D) pFakY397 in T lymphocytes measured by fluorescence-activated cell sorting (C) and quantified by mean fluorescence intensity (MFI) (D).
Data are mean ± SEM. *p < 0.001 compared to WT (Student’s t test).deletion to a lesser degree thanwith five pI:pC treatments. A rela-
tively limited Pten deletionmay enable sufficient time for Pten null
T-ALLcell accumulation, incontrast todeath fromMPDafter com-
plete Pten deletion in mice (Zhang et al., 2006).
After a single pI:pC injection, all Pten/ mice died of T-ALL,
diagnosed by measuring CD4+CD8mid/CD45high LCs (Guo
et al., 2008) in BM and SP (Figure S2E), within 70 days; some
Pten/Fak/ mice began dying of T-ALL on day 50, but most
Pten/Fak/ mice survived significantly longer than Pten/
mice. Approximately 25% of Pten/Fak/ mice were leuke-
mia-free on day 200 post-pI:pC treatment. Fak/ mice are
grossly normal. We confirmed Pten and Fak deletion in T-ALL
cells recovered from moribund mice (Figures 2C and 2D).
On day 45 after a single pI:pC treatment, most Pten/
mice had obvious disease phenotypes, including significantly
enlarged lymph nodes (LNs), THs, and SPs compared to
Pten/Fak/ mice. Pten/ mice had pale-colored livers,
which are typically observed during leukemia development (Fig-
ures 2E–2G). Pten/ mice had significantly greater LC infiltra-
tion into both livers and kidneys (Figure 2H, b and h) and
showed considerable destruction of splenic histologic structure
compared to WT or Pten/Fak/ mice (Figure S2H). At this
stage, Pten/Fak/ mice did not show such a high degree ofCelldisease phenotypes, having larger SPs and LNs than WT or
Fak/ mice (Figures 2E–2G), very low liver or kidney infiltration
(Figure 2H, c and i), and less destruction of splenic histologic
structure (Figure S2H). After T-ALL developed, though still
smaller than Pten/mice, Pten/Fak/mice had significantly
enlarged SPs, LNs, and THs (Figure 2G) and high infiltration of
LCs into livers and kidneys (Figure 2H, f and l), as well as signif-
icant structural destruction of the SP (Figure S2H). To test
whether delayed T-ALL development with Fak deletion was cell
intrinsic, we transplanted CD3+c-Kitlow cells, which are enriched
for T-ALL-initiating cells (Guo et al., 2008), isolated from the BM
of Pten/ or Pten/Fak/ mice (CD45.1+) on day 10 after five
pI:pC treatments into lethally irradiated recipient mice (CD45.2+).
After transplantation, all of the Pten/-recipient mice died of
T-ALL within 125 days; only 55% of Pten/Fak/-recipient
mice died of T-ALL within 150 days, with the remainder of these
mice surviving over 180 days (Figure 2I). These data suggest that
Fak deletion delays T-ALL development in Pten/ mice.
Fak Deletion Partially Restores Apoptosis in Pten/
T-lymphocytes, but Not in Pten/ T-ALL Cells
To investigate the mechanisms by which Fak deletion delays
T-ALL development in Pten/ mice, we analyzed thymocyteReports 10, 2055–2068, March 31, 2015 ª2015 The Authors 2057
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Figure 2. Fak Deletion Significantly Delays the Development of T-ALL in Pten/ Mice
(A and B)Pten and Fak induced deletion efficiency (A) and Pten and Fak protein (B) in c-Kit+ HSPCs and thymocytes on day 10 treatedwith a single pI:pC injection.
(C) Kaplan-Meier survival curve of indicated mice with a single pI:pC injection; compared to Pten/ (p = 0.0054).
(D) Pten and Fak protein in thymocytes recovered from moribund T-ALL mice.
(E and F) Phenotypes on day 45 after a single pI:pC injection. Anatomic mice images: white arrow, lymph nodes (LNs); yellow arrows, thymuses (THs); green
arrows, livers; and red arrows, spleens (SPs) (E). TH, SP, and LN (F). Images shown are representative of five independent experiments.
(G and H) Phenotypes on day 45 and moribund T-ALL mice after single pI:pC injection. Thymocyte number and SP and LN weight: data shown are mean ± SD.
*p < 0.001 compared toWT; $p < 0.001 compared to Pten/ (two-way ANOVA) (G). Images of H&E staining for lymphocytes infiltrated into livers and kidneys (H).
(I) Kaplan-Meier survival curve of recipient mice (CD45.2+) transplanted with CD3+c-Kitlow cells from BM of indicated mice (CD45.1+) on day 10 after five pI:pC
injections. p = 0.009 compared to Pten/-recipient mice. Inset: donor cell genotype immediately prior to transplantation.apoptosis and proliferation on day 10 after five pI:pC injections.
Pten/ mice had fewer apoptotic thymocytes than WT mice.
Increased apoptosis in Pten/Fak/ thymocytes, especially
CD4+CD8 cells, suggests that Fak contributes to the enhanced
survival of Pten/ thymocytes (Figures 3A and 3B). However,
combined Pten and Fak deletion had no significant effect on
apoptosis in CD4CD8, CD4+CD8+, and CD4CD8+ T lympho-
cytes (FiguresS3AandS3B).Fakdeletiondid not change thepro-
liferation of Pten-null cells, which was higher thanWT and Fak/
controls (Figure 3C). Consistent with this, therewas no significant
cell-cycle differencebetweenPten/andPten/Fak/ thymo-
cytes, but both had more cycling cells than did controls (Fig-
ure S3C). After T-ALL development, Pten/Fak/ LCs did not
differ from Pten/ LCs in terms of apoptosis or proliferation
(Figure 3D). These data suggest that Fak deletion delays T-ALL
development in Pten/ mice by partially restoring apoptosis in
thymocytes, especially in CD4+CD8 T lymphocytes, but this
effect disappears after T-ALL development.2058 Cell Reports 10, 2055–2068, March 31, 2015 ª2015 The AuthorFak Promotes a PI3K/Akt/mTOR/Mcl-1-Independent
Survival Signal in Pten/ Thymocytes and T-ALL Cells
by Enhancing the NF-kB/Bcl-2/Bcl-xL Pathway
To study the molecular mechanisms whereby Fak mediated
thymocyte apoptosis, we tested survival-related signals in
Pten/ and Pten/Fak/ thymocytes freshly recovered from
mice on day 10 after five pI:pC treatments. Activation of Akt
and Fak signaling in Pten/ thymocytes was verified by
increased levels of pAkt/pGsk3b and pFAK/pSrc/pP130Cas/
pPaxillin, respectively. Fak deletion reduced the level of the latter
but not the former (Figure 4A). Over-activated PI3K/Akt/mTor
signaling provides a sustained survival signal by upregulating
Mcl-1 in AML, T-ALL and other types of cancer cells (Hsieh
et al., 2010; Inuzuka et al., 2011; Jebahi et al., 2014). Consistent
with these studies, a significant increase of Mcl-1 was detected
in Pten/ thymocytes compared to WT (Figure 4A). This was
not affected by Fak deletion. Comparable Mcl-1 mRNA levels
among WT, Pten/ and Pten/Fak/ thymocytes (Figure 4D)s
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Figure 3. Fak Deletion Partially Restores Apoptosis of Pten/ Thymocytes but Does Not Affect the Survival or Proliferation of Pten Null
T-ALL Cells
(A and B) Apoptosis by Annexin V staining: total thymocytes and CD4+CD8 T lymphocytes before T-ALL development after a single pI:pC injection.
(C) Bromodeoxyuridine pulse-labeled thymocytes prior to T-ALL development.
(D) Apoptosis and proliferation analysis of T-ALL cells from Pten/ or Pten/Fak/ mice.
Data are mean ± SD. *p < 0.001 compared to WT; $p < 0.001 compared to Pten/; n.s, no significant difference (two-way ANOVA).supported the idea that Mcl-1 is regulated by PI3K/Akt/mTor
through a post-transcriptional mechanism (Hsieh et al., 2010;
Inuzuka et al., 2011).
NF-kBmediates a critical survival signal in many types of can-
cers by enhancing the expression of several key survival genes,
such as Bcl-2 and Bcl-xL (Karin, 2006). To determine whether
NF-kB mediates a Fak-stimulated PI3K/AKT-independent sur-
vival signal in Pten/ thymocytes, we measured NF-kB activity
in these cells by assessing whole-cell pP65 and nuclear P65.
NF-kB activation was greatly enhanced in Pten/ thymocytes
compared to WT. However, in Pten/Fak/ thymocytes, NF-
kB activity was reduced compared to Pten/ (Figures 4A and
4C), suggesting Fak-dependent NF-kB activation in Pten/
cells. As a consequence, mRNA and protein levels of Bcl-xL
and Bcl-2, known downstream target genes of NF-kB, were up-
regulated in Pten/ thymocytes and repressed by Fak deletion
(Figures 4A and 4D). The comparable expression of other knownCellNF-kB target genes such as cIAP1/2, Cyclin D1/2, and Cyclin A2
in WT and Pten-null thymocytes suggested that not all NF-kB
target genes were induced by Pten deletion. The expression of
p57, p21, p27, and p-Rb, all negative cell-cycle regulators,
was not altered in Pten-null cells (Figures S4A and S4B).
Enhanced c-Myc and p-H3 (a mitotic marker) in both Pten/
and Pten/Fak/ thymocytes might explain the increased
proliferation of Pten-null cells compared to WT (Figure 3C;
Figures S4A and S4B). Moreover, Pyk2 activity, a homolog of
Fak with a potential compensatory effect for Fak deletion, and
Jnk1/2, another potential survival pathway to neutralize the
inactivation of NF-kB (Volk et al., 2014), were measured. There
was a negligible difference between Pten/ and Pten/Fak/
thymocytes, yet p-Jnk1/2 was at a higher level than WT
(Figure S4B).
Although Fak deletion significantly enhanced survival, most
Pten/Fak/ mice still developed T-ALL after a single pI:pCReports 10, 2055–2068, March 31, 2015 ª2015 The Authors 2059
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Figure 4. Two Parallel Survival Signaling Pathways, PI3K/Akt/mTOR/Mcl-1 and Fak/NF-kB/Bcl-xL/Bcl-2, in Pten/ Thymocytes and T-ALL
Cells
(A and B) pFak, pSrc, pP130Cas, pPaxillin, pP65, pAkt, pGsk3b, Bcl-xL, Bcl-2, and Mcl-1 expression in thymocytes before T-ALL development (A) and in T-ALL
cells (B).
(C) Nuclear (N) and cytoplasmic (C) P65 in thymocytes (left) or T-ALL cells (right). Images are representative of five independent experiments.
(D) mRNA levels of Mcl-1, Bcl-xL, and Bcl-2 in thymocytes before T-ALL development and in T-ALL cells, with WT as controls.
Data are mean ± SD. *p < 0.001 compared to WT; $p < 0.001 compared to Pten/ (two-way ANOVA).treatment (Figure 2C). Inactivation of NF-kB/Bcl-xL/Bcl-2
signaling in Pten/Fak/ T-ALL cells might be compensated
by a Fak-independent signal(s). We recovered T-ALL cells from
both Pten/ and Pten/Fak/ mice to test this possibility.
Pten/Fak/ cells had lower NF-kB activity and reduced Bcl-
2/Bcl-xL than Pten/ (Figures 4B and 4C). Interestingly, we
found significantly enhanced PI3K/Akt/mTOR signaling and
further increased Mcl-1 in Pten/Fak/ compared to Pten/
T-ALL cells (Figure 4B). This indicated that further enhancement
of PI3K/Akt/mTOR/Mcl-1 signaling could compensate for inacti-
vated Fak/NF-kB/Bcl-xL/Bcl-2 signaling in Pten/Fak/ cells
to promote T-ALL development and progression. These data
suggest that PI3K/Akt/mTOR/Mcl-1 and Fak/NF-kB/Bcl-xL/
Bcl-2 mediate two parallel survival signaling pathways, which
are normally restricted by Pten, in Pten-null thymocytes and
T-ALL cells.2060 Cell Reports 10, 2055–2068, March 31, 2015 ª2015 The AuthorFak Deletion Restores the Sensitivity of Pten-Null
Thymocytes and T-ALL Cells to PI3K/mTOR/Mcl-1
Inhibitors In Vitro
When cultured in suspension without feeder cells or extracellular
matrix (ECM) coating (hereafter ‘‘suspension’’), both Pten/
and Pten/Fak/ thymocytes and T-ALL cells were sensitive
to a pan-PI3K inhibitor, LY294002 (LY), mTOR inhibitors,
KU0063794 (KU)/rapamycin (RA), andMcl-1 inhibitor (MI); no dif-
ference was observed between Pten/ and Pten/Fak/ cells
(Figures 5A and 5B, leftmost panels). Because Fak is activated
by ECM signals (Mitra and Schlaepfer, 2006), we speculated
that Fak might not be activated in suspension culture. We
measured Fak activation in freshly recovered and suspension-
cultured Pten/ thymocytes and T-ALL cells. Compared to
freshly recovered cells, Fak activation was much lower in sus-
pension-cultured cells. Grown on OP9 feeder layer cells (OP9),s
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Figure 5. Inhibition of Fak/NF-kB Signaling Sensitizes Pten/ Thymocytes and T-ALL Cells to PI3K/mTOR/Mcl-1 Inhibition In Vitro and
In Vivo
(A and B) Sensitivity of thymocytes (A) and T-ALL cells (B) to DMSO (DO), LY, KU, RA, MI, and LY + PF when cultured in suspension, on OP9 feeder cells, or on
MG-coated plates, respectively;WT, control. Data shown are mean ± SD. *p < 0.001 compared to DMSO; $p < 0.001 compared toWT; #p < 0.001 compared to
Pten/; ₤p < 0.001 compared to LY treatment (two-way ANOVA).
(legend continued on next page)
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or on Matrigel (MG)-, collagen (CLG)-, or fibronectin (FN)-coated
plates, Fak could be activated to a level comparable to freshly
recovered cells (Figures S5A and S5B). Fak activation by OP9
or MG/CLG/FN-coated plates enabled Pten/ thymocytes
and T-ALL cells to become less sensitive to PI3K/mTOR/Mcl-1
inhibitors, which were titrated to optimize treatment concentra-
tions (Figure S5C), although they were still more sensitive to
these inhibitors than WT cells. Pten/Fak/ demonstrated
increased death compared to Pten/ cells upon PI3K/Akt signal
inhibition by LY, KU, RA, or MI. Consistent with the genetic inac-
tivation of Fak, suppression of both PI3K/Akt and Fak signals (by
the FAK inhibitor PF573228 [PF]) with combined pharmacolog-
ical inhibitors (LY + PF) caused more death in Pten/ cells
than with the individual inhibitor LY (Figures 5A and 5B; Figures
S5D and S5E). To test whether the increased death induced by
Fak deletion was due to its kinase activity, we overexpressed
FakWT or FakY397F (kinase null) in Pten/Fak/ thymocytes
and T-ALL cells. Expression of FakWT, but not FakY397F,
increased survival of Pten/Fak/ cells treated with LY, KU,
RA, or MI (Figure S5F; Figures 5C–5E). These data suggest
that Fak activation by OP9 or ECM-coated plates increases the
resistance of Pten/ thymocytes and T-ALL cells to PI3K/Akt/
mTOR/Mcl-1 inhibition.
Fak Inactivation Increases the Sensitivity of Pten-Null
T-ALL Cells to Apoptosis Induced by PI3K/mTOR
Inhibitors In Vivo
We transplanted CD3+c-Kitlow cells from Pten/ T-ALL mice
(CD45.1+) into lethally irradiated recipient mice (CD45.2+).
Beginning on day 14 after transplantation, we treated recipient
mice with KU at 30 mg/kg and/or PF at 50 mg/kg, alone or
together, every other day until analysis or death of the animal
(maximum of 15 injections). Either KU or PF alone significantly
enhanced the survival of recipient mice compared to vehicle
treatment. KU + PF treatment further increased the survival
compared to either single inhibitor treatment (Figure S5G). We
next tested whether Fak inhibition could enhance the therapeu-
tic effects of PI3K/Akt/mTOR inhibitors on Pten-null T-ALL mice.
Immediately following T-ALL development, diagnosed by >30%
blasts (Figures S2F and S2G) and 35,000–60,000 ml1 WBCs
(Figure 5H) in their PB, we treated Pten/, Pten/Fak/
mice with LY at 40 mg/kg (Hu et al., 2002; Nagata et al., 2004)
or KU at 30 mg/kg every other day until analysis or a maximum
15 injections. After five drug treatments, we analyzed T-ALL cell
apoptosis. Pten/ T-ALL cells underwent apoptosis to a greater
extent with LY or KU than with vehicle treatment. Pten/Fak/
T-ALL cells underwent apoptosis to an even greater extent than(C–E) Sensitivity of Fak-overexpressing Pten/Fak/ thymocytes and T-ALL ce
procedure (C); Pten and Fak protein in transduced cells (D). Sensitivity of transduc
as controls. Data are mean ± SD. *p < 0.001 compared to Migr1-Pten/; $p < 0
(F and G) Apoptosis of T-ALL cells from leukemic Pten/ and Pten/Fak/mice
Annexin V+ cells (G). Data are mean ± SEM. *p < 0.001 compared to WT; $p < 0
(H) Kaplan-Meier survival curve for Pten/ and Pten/Fak/ T-ALL mice trea
treatment toxicity. Upper panel: WBC counts and Giemsa staining of PB of Pten
(I) Kaplan-Meier survival curve of recipient mice (CD45.2+) transplanted with CD3
mice (CD45.1+) treated with vehicle, LY, or KU. *Compared to corresponding vehi
KU treatment.
2062 Cell Reports 10, 2055–2068, March 31, 2015 ª2015 The AuthorPten/ (Figures 5F and 5G). Pten/ mice survived longer with
LY or KU compared to vehicle treatment; Pten/Fak/ mice
survived even longer than Pten/, and 25% were still alive
more than 60 days after the first drug treatment. To rule out
the treatment toxicity, we treated WT mice with LY or KU at
the same time; no WT mice died (Figure 5H). To determine
whether the role of Fak in Pten null T-ALL was cell intrinsic,
we transplanted CD3+c-Kitlow cells from either Pten/ or
Pten/Fak/ T-ALL or WT mice (CD45.1+) into lethally irradi-
ated recipient mice (CD45.2+). Recipient mice were treated
with vehicle, LY, or KU from day 14 post-transplantation every
other day until analysis or a maximum of 15 injections. LY and
KU enhanced the survival of Pten/-recipient mice compared
to vehicle treatment. Pten/Fak/-recipient mice survived
longer than Pten/-recipient mice, whether treated with
vehicle, LY, or KU. With LY or KU treatment, 25% or 40% of
Pten/Fak/-recipient mice survived more than 120 days after
the first drug treatment, respectively (Figure 5I). To further rule
out in vivo toxicity of LY, we treated Pten/ and Pten/Fak/
transgenic or transplanted T-ALL mice with another pan-PI3K
inhibitor, GDC-0941 (GDC) (Folkes et al., 2008). Similar results
were observed in treatments with GDC as with LY (Figures
S5H and S5I). These data suggest that Fak deletion makes
Pten-null T-ALL cells more sensitive to PI3K/AKT/mTOR inhibi-
tion in vivo.
FAK/NF-kB/Bcl-xL/Bcl-2 and PI3K/AKT/mTOR/Mcl-1
Provide Two Independent Survival Signals in PTEN
Mutant Human T-ALL Cell Lines
When cultured on MG-coated plates, both FAK and AKT signals
were activated in PTEN null human T-ALL cell lines (JURKAT,
CCRF-CEM, MOLT-4, and LOUCY), but not in PTEN-WT cell
lines (CUTLL1, HPB-ALL, or KOPT-K1) (Figure 6A). This result
was confirmed in JURKAT and HBP-ALL cells, when grown
on OP9 cells or on CLG/FN-coated plates (Figure S6A). Pten
regulates the activity of Fak in NIH 3T3 cells (Tamura et al.,
1998). To test whether FAK activation was also regulated
by PTEN in human T-ALL cells, we expressed PTEN-WT,
PTENC124S, PTENY138L, and PTENG129E in JURKAT cells cultured
on MG-coated plates. PTENWT repressed the activities of both
AKT and FAK; PTENC124S, a phosphatase-null mutant, did not
inhibit either signal; PTENY138L, a protein-phosphatase-inactive
mutant, suppressed only AKT activity; and the lipid-phospha-
tase-null mutant, PTENG129E, restrained only FAK activity (Fig-
ure 6B). Immunoprecipitation using PTEN or FAK antibodies
in these transduced JURKAT cells demonstrated that PTEN
could bind to FAK in a phosphatase-activity-independentlls to DO, LY, KU, RA, or MI when cultured on MG-coated plates. Experimental
ed cells on MG-coated plates (E) usingMigr1 (empty vector)-transduced cells
.001 compared to migr1-Pten/Fak/ (two-way ANOVA).
on day 10 with vehicle, LY, or KU treatment (F), and statistical quantification of
.001 compared to Pten/ (Student’s t test).
ted with vehicle, LY, or KU; WT mice were treated with LY or KU to evaluate
/ and Pten/Fak/ T-ALL mice, using WT as control.
+c-Kitlow cells isolated from BM of Pten/ or Pten/Fak/ T-ALL mice orWT
cle treatment. $Compared to Pten/mice with corresponding vehicle or LY or
s
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Figure 6. PI3K/AKT/mTOR/MCL-1 and FAK/NF-kB/BCL-xL/BCL-2 Represent Two Parallel Survival Signaling Pathways in PTEN Mutant
Human T-ALL Cell Lines
(A) PTEN, pFAK, pSRC, pAKT, and pS6K expression in human T-ALL cell lines, CUTLL1, JURKAT, CCRF-CEM, HPB-ALL, MOLT-4, LOUCY, and KOPT-K1,
cultured on MG-coated plates.
(B) PTEN, pFAK, and pAKT in PTENWT or PTENC124S-, PTENG129E-, or PTENY138L-transduced JURKAT cells cultured on MG-coated plates; control: empty vector
(EV)-transduced cells.
(C and D) The binding of PTEN and FAK in transduced JURKAT cells (C) and HBP-ALL cells (D).
(legend continued on next page)
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manner (Figure 6C). The interaction of endogenous PTEN
and FAK was verified in HPB-ALL cells (Figure 6D). Though
PTEN can bind FAK in cells, it is still possible that PTEN dephos-
phorylated FAK indirectly. These data suggest that the activities
of both AKT and FAK are regulated by PTEN in human T-ALL
cells.
To explore the effect of AKT and/or FAK signal inhibition on
human T-ALL cell lines cultured in suspension, or on OP9 or
MG/CLG/FN-coated plates, we treated the cells with PI3K/
mTOR/MCL-1 and FAK/SRC inhibitors, which were titrated to
optimize concentrations (Figure S6B), alone or in combination.
In suspension culture, the survival of JURKAT (PTEN-null) cells
was highly restrained by PI3K, mTOR, or MCL-1 inhibitors, but
there was no further restrained effect with combined inhibition
of both AKT and FAK signaling. When cultured on OP9 or
MG/CLG/FN-coated plates, JURKAT cells were less sensitive
to AKT signaling inhibition, which was further suppressed with
combined AKT and FAK signaling inhibition. However, CUTLL1
(PTEN-WT) cells did not respond to the inhibition of AKT,
FAK alone, or both (Figure 6E). We confirmed this result with
other PTEN-null (CCRF-CEM, MOLT-4, LOUCY) and PTEN-
WT (HPB-ALL, KOPT-K1) human T-ALL cell lines (Figure S6D).
The colony-forming ability of JURKAT cells was more dramati-
cally reduced by the combined inhibition of AKT and FAK
signaling compared to the inhibition of either alone (Figure 6F)
at optimized concentrations (Figure S6C). To study the molecu-
lar mechanisms of survival signals in PTEN-null human T-ALL
cells, we treated JURKAT cells with PI3K/AKT/mTOR/MCL-1
inhibitors (LY, KU, RA, and MI) or FAK signal inhibitors (PF
and SRC inhibitor [SI]) cultured on MG-coated plates. Inhibition
of the PI3K/AKT signal did not change the expression of BCL-xL
or BCL-2, but it significantly reduced MCL-1. Inhibition of FAK
signal reduced the expression of both BCL-xL and BCL-2;
so did the restriction of NF-kB by Bay 11-7085 (BA). Similar
to what we observed in Pten/Fak/ T-ALL mouse cells,
enhanced AKT signaling and further increased MCL-1 were
also detected when FAK activity was suppressed in JURKAT
cells (Figure 6G).
As observed with pharmacologic inhibitor treatment, short
hairpin RNA (shRNA) restriction of FAK suppressed NF-kB activ-
ity, as shown by reduced protein level (Figure 6H) and P65 nu-
clear localization (Figure S6E). Suppression of FAK by shRNA
made JURKAT cells more sensitive to the inhibition of PI3K/
AKT signal by LY, KU, RA, or MI treatment, displaying reduced
viability on MG-coated plates (Figure 6I) or OP9 (Figure S6F)
and colony-forming ability (Figure 6J).(E) Viability of human T-ALL cell lines in suspension, on OP9, or onMG/CLG/FN-co
PF, RA + PF, andMI + PF. Data shown aremean ± SD. ***p < 0.001 and *p < 0.05 c
culture; ###p < 0.001 compared to single inhibitor treatment.
(F) Colony number of JURKAT cells treatedwith DO, LY, KU, RA, orMI, alone or in c
treatment; $p < 0.001 compared to single-inhibitor treatment,.
(G) pFAK, pSRC, pP65, pAKT, pS6K, BCL-xL, BCL-2, andMCL-1 expression in JU
SI, or BA, respectively.
(H) Nuclear (N) and cytoplasmic (C) P65 in JURKAT cells with knockdown of FAK
(I and J) Viability, cultured onMG-coated plates (I), and colony-forming ability (J) o
Data shown are mean ± SD. *p < 0.001 compared to DO treatment; $p < 0.001 c
(K) The levels of pFAK, pPAK1, pP65, and the expression of PTEN, RAC1/CDC42
representative of three independent experiments. All statistical values were dete
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GTPase- or RIP1-dependent manner in cancers (Kamarajan
et al., 2010; Tong and Tergaonkar, 2014). To determine which
pathway mediated the activated Fak-promoting NF-kB activity
in Pten-null T-ALL cells, we tested the expression and activity
of Rac1/Cdc42 (assessed by pPak1), which were not affected
by Fak deletion (Figure S4B). Rac-GTPase inhibitor, EHop-016
(EH), failed to repress NF-kB activity in JURKAT (PTEN-null)
cells. However, a Smac mimetic (inhibiting NF-kB activity by re-
pressing c-IAP1/2-mediated RIP1 ubiquitination; Wang et al.,
2008), birinapant (BI), restrained NF-kB activity in JURKAT
cells. Neither inhibitor changed NF-kB activity in HBP-ALL
(PTEN-WT) cells (Figure 6K). This indicated that FAK activated
NF-kB through RIP1, not Rho/Rac, in PTEN-null T-ALL cells.
To address whether the reduction in BCL-xL and BCL-2
expression was caused by inhibition of NF-kB, we treated
JURKAT, KOPT-K1, and CCRF-CEM with BA (inhibiting NF-
kB) or ABT-737 (BCL-xL/BCL-2 inhibitor) on MG-coated plates.
In PTEN-mutant cell lines, JURKAT and CCRF-CEM, inhibition
of NF-kB reduced BCL-xL/BCL-2, but inhibition of BCL-xL/
BCL-2 did not affect NF-kB activity, as measured by pP65
and nuclear P65 (Figures S7A and S7B). This indicated that
BCL-xL and BCL-2 were regulated by NF-kB in PTEN-null
human T-ALL cell lines.
PTEN Mutant Human Primary T-ALL Cells Are More
Sensitive toCombined TreatmentUsing PI3K/mTORand
FAK Inhibitors Than to Treatment with Either Inhibitor
Alone
We collected and cultured primary T-ALL patient samples and
CD3+ lymphocytes from healthy subjects on MG-coated plates
and assessed the activation of AKT and FAK signals. In two of
three PTEN-positive samples (patients 1 and 4), neither signal
was activated. All PTEN-negative samples and one PTEN-posi-
tive sample (patient 7) showed increased activation of both AKT
and FAK signals (Figure 7A). We considered that patient 7 might
contain a loss-of-function PTEN mutation, which is commonly
associated with human T-ALL (Zuurbier et al., 2012), but this
could not be determined due to limited cell availability. Cells
were treated with PI3K/mTOR or FAK inhibitors, alone or in com-
bination. The specific inhibitory activities of these chemicals on
primary T-ALL cells were verified bywestern blot (Figure 7B). Un-
like healthy CD3+ cells, the survival of all primary T-ALL cells
could be restricted to some extent by either PI3K/mTOR
or FAK inhibition; however, PTEN-negative and patient 7 cells
were significantly more sensitive to combined treatmentated plates, treated with DMSO (DO), LY, KU, RA, MI, and PF or LY + PF, KU +
ompared to DO treatment; $$$p < 0.001 and $p< 0.05 compared to suspension
ombination with PF or SI. Data shown aremean ±SD. *p < 0.001 comparedDO
RKAT cells cultured onMG-coated plates treated with DO, LY, KU, RA, MI, PF,
by shRNA. Data shown are mean ± SD. *p < 0.001 compared to scrambled,.
f JURKAT cells to FAK inhibition by shRNA, treated with DO, LY, KU, RA, or MI.
ompared to scrambled.
, and c-IAP1 in JURKAT and HBP-ALL cells. Images shown in western blot are
rmined by two-way ANOVA.
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Figure 7. PTEN-Mutant Human Primary T-ALL Cells Are More Sensitive to Combined Treatment Using PI3K/mTOR and FAK Inhibitors Than
to Either Inhibitor Alone
(A) PTEN, pFAK, pSRC, pAKT, pGSK3b, and pS6K expression in primary human T-ALL cells cultured onMG-coated plates; controls: healthy CD3+ lymphocytes.
(B) pFAK and pAKT in patient 2 samples (PTEN null) treated with DMSO (DO), LY, KU, PF, or LY + PF, KU + PF. Images are representative of three independent
experiments.
(C) Primary human T-ALL cell viability after treatment with DO, LY, KU, PF, or LY + PF, KU + PF; controls: healthy CD3+ lymphocytes. Data shown are mean ± SD.
***p < 0.001, **p < 0.01, *p < 0.05 compared to healthy controls; $$$p < 0.001 compared to single-inhibitor treatment (two-way ANOVA).
(D) Schematic model of two parallel survival signals in PTEN-mutant T-ALL cells.(LY + PF/KU + PF) than to treatment with either single inhibitor,
but PTEN-WT or healthy controls were not (Figure 7C). These
data suggest that simultaneous inhibition of both PI3K/AKT/
mTOR and FAK/NF-kB signaling might represent a more effec-
tive treatment strategy for PTEN-null T-ALL.
DISCUSSION
In PTEN-null, but not in PTEN-WT, murine and human T-ALL
cells, both AKT and FAK signals are activated in vivo or whenCellcultured on a feeder layer or ECM-coated plates. We determined
that PI3K/AKT acts throughmTORand FAKworks viaNF-kB, up-
regulating distinct survival genes (MCL-1 and BCL-2/BCL-xL,
respectively). Thus, two parallel survival signaling pathways are
stimulated in PTEN-mutant T-ALL cells (Figure 7D). Inhibition of
PI3K/AKT/mTOR signaling induces apoptosis and represses
the growth of T-ALL cells, which sensitizes drug-resistant
T-ALL cells to conventional chemotherapy (Evangelisti et al.,
2011; Piovan et al., 2013; Subramaniamet al., 2012). These inhib-
itors are currently in clinical trials in T-ALL patients, but noReports 10, 2055–2068, March 31, 2015 ª2015 The Authors 2065
complete remission was reported with these inhibitor treatments
(Rodon et al., 2013). We found that suppression of FAK further
enhanced the inhibitory effects of PI3K/AKT signal restriction
on PTEN-null T-ALL cells. FAK inhibitors are also in clinical trials
for treatment of solid tumors and have been approved as rela-
tively safe and promising drugs (Golubovskaya, 2014). Our study
provides a strong rationale to treatPTEN-mutant T-ALL by co-in-
hibition of bothAKT- andFAK-stimulatedparallel survival signals.
Both the lipid and protein phosphatase activities of PTENwere
well demonstrated in earlier studies (Lee et al., 1999; Tamura
et al., 1998). However, the pathophysiologic role downstream
of PTEN’s protein phosphatase activity hasbeen underestimated
in leukemogenesis because inactivation of its phosphatase or
constitutive activation of its lipid substrates is sufficient to induce
tumors in mice (Kharas et al., 2010; Myers et al., 1998; Wang
et al., 2010). Nevertheless, transgenic overexpression of active
PI3K or AKT fails to faithfully replicate the Pten/ phenotype,
suggesting a PI3K/AKT-independent function of PTEN (Blanco-
Aparicio et al., 2007). Several direct substrates of PTEN’s protein
phosphatase, such as IRS1 and CREB, have been defined (Gu
et al., 2011; Shi et al., 2014; Tibarewal et al., 2012). We deter-
mined that the ECM activates FAK in PTEN mutant T-ALL cells,
providing an additional layer of survival/proliferation signaling to
promote the initiation and progression of leukemia, together
with PI3K/AKT signaling. PTEN-mutant T-ALL cells are sensitive
to inhibition of non-canonical PI3K signaling, both when cultured
on MS5-DL feeder cells and in vivo (Subramaniam et al., 2012).
Consistent with this report, we found that PI3K/AKT inhibitors
are effective in killing PTEN-null, but not PTEN-WT, T-ALL cells
both in vitro and in vivo. However,PTEN-null T-ALL cells are rela-
tively resistant to these inhibitors when grown on stromal feeder
cells or ECM-coated plates compared to suspension culture.
Further study suggested that inactivation of both FAK and
PI3K/AKT signals might provide a better treatment for PTEN-
null T-ALL than inhibition of PI3K/AKT alone. Furthermore, in
our study of primary human T-ALL cells, we began with 14 sam-
ples, of which 8were able to growonMG-coated plates. Of these
8 samples, 6 of them (75%) showedPTEN inactivation.Given that
PTENmutations aregenerally reported in 15%–25%ofT-ALLpa-
tients (Gutierrez et al., 2009; Jotta et al., 2010; Zuurbier et al.,
2012), we believe that MG-coated culture selectively favors the
growth of PTEN-null T-ALL cells.
BothMCL-1 and BCL-xL/BCL-2 are highly expressed in T-ALL
cells, and they functionally compensate for each other to support
LC survival. Simultaneously inhibiting both MCL-1 and BCL-2/
BCL-xL shows an additive effect in killing T-ALL LCs (Inuzuka
et al., 2011). The activated AKT signal increases MCL-1 (Hsieh
et al., 2010; Inuzuka et al., 2011; Jebahi et al., 2014), and
we demonstrated that FAK/NF-kB signal activated by ECM
of niches enhances BCL-xL/BCL-2 in PTEN-null T-ALL cells.
Further studies of these signaling mediators could produce
favorable drug targets for T-ALL treatment.EXPERIMENTAL PROCEDURES
Mice and Drug Treatments
Fakfx/fx mice (stock number 009967-UCD) were purchased from Mutant Mice
Regional Resource Center. Mx-1-Cre+Ptenfx/+ mice were maintained in our2066 Cell Reports 10, 2055–2068, March 31, 2015 ª2015 The Authorlaboratory (Zhang et al., 2011). Drug treatments were conducted as indicated
in Supplemental Experimental Procedures.
T-ALL Transplantation and In Vivo Treatments
CD3+c-KitLow cells were isolated from Pten/ or Pten/Fak/ T-ALL
or WT mice (CD45.1+) and transplanted into lethally irradiated recipient
mice (CD45.2+) together with support BM cells (CD45.2+). Each mouse
received 1 3 104 T-ALL cells and 2 3 105 support BM cells. Drug treatments
were conducted as described in Supplemental Experimental Procedures.
Flow Cytometry and Antibodies
BM, SPs, THs, and PBwere collected after the mice had been sacrificed. MNC
were isolated from these tissues after red blood cell lysis. Cells were sus-
pended in fluorescence-activated cell sorting buffer (13 PBS supplemented
with 2% FBS) at a concentration of 1 3 107 cells/ml and aliquoted into flow
cytometry tubes (100 ml per tube) for antibody staining. Antibodies used in
this study were purchased from eBioscience. See Supplemental Experimental
Procedures for more information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.02.056.
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